CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when com...
Phase 3
Rochester, Minnesota, United States and 232 other locations
drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...
Phase 1
Rochester, Minnesota, United States and 73 other locations
first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer...
Phase 1
Rochester, Minnesota, United States and 13 other locations
can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will also look at the leve...
Phase 1, Phase 2
Rochester, Minnesota, United States and 53 other locations
-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer...
Phase 1, Phase 2
Rochester, Minnesota, United States and 123 other locations
to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combinatio...
Phase 1
Rochester, Minnesota, United States and 55 other locations
with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 56 other locations
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like you...
Phase 1
Rochester, Minnesota, United States and 23 other locations
Clinical trials
Research sites
Resources
Legal